Press Releases

10.04.2018

Pfizer to Award More Than $3 Million in Grants to Further Breast Cancer Research

10.01.2018

Pfizer Announces CEO Succession

09.27.2018

U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

09.27.2018

Pfizer Declares 34-Cent Fourth-Quarter 2018 Dividend

09.20.2018

Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older

09.18.2018

Pfizer Invites Public to View and Listen to Webcast of October 30 Conference Call with Analysts

09.18.2018

New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting

09.17.2018

ATOMWISE ENTERS INTO AN EVALUATION AGREEMENT WITH PFIZER

09.14.2018

Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress

09.12.2018

System1 Announces a $25 Million Series A Funding to Advance Integrated Technology Platform for Neurotherapeutics Discovery

09.11.2018

BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients with Advanced Renal Cell Carcinoma in Phase III Study

09.06.2018

CYTOO enters into Research and Option Agreement with Pfizer to develop a target discovery platform for Duchenne Muscular Dystrophy